Global Graft Versus Host Disease (GvHD) Treatment Market 2023
The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global GvHD treatment market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors approaches.
Market Segmentation
The market is segmented based on various factors, including drug class, treatment type, gender, and geography.
Drug class: calcineurin inhibitors, corticosteroids, kinase inhibitors, TNF-alpha inhibitors, others
Treatment type: acute GvHD, chronic GvHD, GvHD prophylaxis
Gender: females, males
Segmentation by Geography
North America US
Europe Germany, France, UK, Italy, Spain
APAC - China, Japan
Corticosteroid drugs are projected to hold a significant share in the global GvHD treatment market, with kinase inhibitors expected to be the fastest-growing segment. Corticosteroids are commonly recommended as front-line therapy due to their safety and efficacy compared to alternative drugs. Acute GvHD is anticipated to contribute significantly to the market, affecting 30% to 50% of individuals undergoing stem cell transplantation. Males currently dominate the market, but females are projected to be the fastest-growing segment. The United States is currently dominant, but China is expected to exhibit faster growth. Factors driving the US market include increasing incidence of GvHD, presence of key players, and improved healthcare accessibility.
Competitive Landscape
Key players in the GvHD treatment market include AltruBio, Inc., ASC Therapeutics Inc., Bristol-Myers Squibb Company, Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd., Elsalys Biotech SAS, Equillium, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., GSK plc, Incyte Corporation, Janssen Global Services, LLC, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co., Ltd., Kadmon Corporation (Sanofi S.A.), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics, Inc., Neovii Pharmaceuticals AG, Novartis AG, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Xenikos B.V., among others.
Scope of the Report
To analyze and forecast the market size of the global GvHD treatment market.
To classify and forecast the global GvHD treatment market based on drug class, treatment type, gender, geography.
To identify drivers and challenges for the global GvHD treatment market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global GvHD treatment market.
To identify and analyze the profile of leading players operating in the global GvHD treatment market.
Why Choose This Report
Gain a reliable outlook of the global GvHD treatment market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Companies Mentioned
AltruBio Inc., ASC Therapeutics Inc., Bristol-Myers Squibb Company, Chia Tai-Tianqing Pharmaceutical Holdings Co. Ltd., Elsalys Biotech SAS, Equillium Inc., F. Hoffmann-La Roche AG, Genentech Inc., GSK plc, Incyte Corporation, Janssen Global Services LLC, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co. Ltd., Kadmon Corporation (Sanofi S.A.), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics Inc., Neovii Pharmaceuticals AG, Novartis AG, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Xenikos B.V.
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
2.1 Primary Research
2.2 Secondary Research
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
4.1 Introduction
4.2 Drivers
4.3 Restraints
PART 5. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY DRUG CLASS
5.1 Calcineurin inhibitors
5.2 Corticosteroids
5.3 Kinase inhibitors
5.4 TNF-alpha inhibitors
5.5 Others
PART 6. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY TREATMENT TYPE
6.1 Acute GVHD
6.2 Chronic GVHD
6.3 GVHD prophylaxis
PART 7. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY GENDER
7.1 Females
7.2 Males
PART 8. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY GEOGRAPHY
8.1 North America
8.2 Europe
8.3 APAC
PART 9. COMPANY PROFILES
9.1 AltruBio, Inc.
9.2 ASC Therapeutics Inc.
9.3 Bristol-Myers Squibb Company
9.4 Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.
9.5 Elsalys Biotech SAS
9.6 Equillium, Inc.
9.7 F. Hoffmann-La Roche AG
9.8 Genentech, Inc.
9.9 GSK plc
9.10 Incyte Corporation
9.11 Janssen Global Services, LLC
9.12 Jazz Pharmaceuticals plc
9.13 JCR Pharmaceuticals Co., Ltd.
9.14 Kadmon Corporation (Sanofi S.A.)
9.15 MaaT Pharma SA
9.16 Mallinckrodt PLC
9.17 medac GmbH
9.18 Merck Corporation
9.19 Mesoblast Limited
9.20 MiNK Therapeutics, Inc.
9.21 Neovii Pharmaceuticals AG
9.22 Novartis AG
9.23 Pharmacyclics LLC
9.24 Pluri Inc.
9.25 REGiMMUNE Corporation
9.26 Sun Pharmaceutical Industries Ltd.
9.27 Syndax Pharmaceuticals, Inc.
9.28 Takeda Pharmaceutical Company Limited
9.29 Xenikos B.V.
DISCLAIMER
Global Whole Exome Sequencing Market 2023
DescriptionThe Whole Exome Sequencing Market is poised for substantial growth, with a projected increase from USD 1.43 billion in 2022 to USD 3.75 billion by 2029. This growth is expected
USD 1950 View ReportGlobal Continuous Bioprocessing Market 2023
DescriptionThe global Continuous Bioprocessing Market size is anticipated to expand from USD 133.9 million in 2022 to USD 443.1 million by 2029, registering a compound annual growth rate (CAGR) of
USD 1950 View ReportGlobal Graft Polyols Market Research Report 2021-2025
In this report, the global Graft Polyols market is valued at USD XX million in 2021 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2021 to 2025.
USD 2850 View ReportGlobal Graft Polyol Market Report 2019, Competitive Landscape, Trends and Opportunities
The Graft Polyol market has witnessed growth from USD XX million to USD XX million from 2014 to 2019. With the CAGR of X.X%, this market is estimated to reach
USD 2950 View ReportFill The Form For Sample Request